BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response. OBJECTIVE: To clarify the role of immune check point inhibitors in GBM management. METHODS: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials.gov and abstracts recently presented at international congresses. RESULTS: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management. CONCLUSION: Immune check-point inhibitors should be considered a promising treatment option in GBM.
New approaches in glioblastoma multiforme: the potential role of immune-check point inhibitors / DE FELICE, Francesca; Musio, Daniela; Cassese, Raffaele; Gravina, GIOVANNI LUCA; Tombolini, Vincenzo. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - STAMPA. - 17:3(2017), pp. 282-289. [10.2174/1568009616666160813183738]
New approaches in glioblastoma multiforme: the potential role of immune-check point inhibitors
DE FELICE, FRANCESCA
Primo
;CASSESE, RAFFAELE;GRAVINA, GIOVANNI LUCAPenultimo
;TOMBOLINI, VincenzoUltimo
2017
Abstract
BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response. OBJECTIVE: To clarify the role of immune check point inhibitors in GBM management. METHODS: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials.gov and abstracts recently presented at international congresses. RESULTS: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management. CONCLUSION: Immune check-point inhibitors should be considered a promising treatment option in GBM.File | Dimensione | Formato | |
---|---|---|---|
De Felice_New_2017.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
4.14 MB
Formato
Adobe PDF
|
4.14 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.